Boston Scientific (BSX) jumps as Q4 results exceed analyst expectations

Go back to Boston Scientific (BSX) jumps as Q4 results exceed analyst expectations

Boston Scientific (BSX) Tops Q4 EPS by 4c, Beats on Revenue; Offers Guidance

January 31, 2024 6:32 AM EST

Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.55, $0.04 better than the analyst estimate of $0.51. Revenue for the quarter came in at $3.73 billion versus the consensus estimate of $3.6 billion.

The company estimates net sales growth for the full year 2024, versus the prior year period, to be in a range of... More